'Effect of CRT on Defibrillation Threshold Estimates' Study

Status Completed

Clinical Trial Summary

The purpose of this prospective study is to evaluate the effect of cardiac resynchronization therapy (CRT) on the defibrillation threshold (DFT) estimates in cardiac resynchronization therapy defibrillators (CRT-D) patients. The hypothesis of the study is that defibrillation threshold (DFT) will decrease with 6 months of cardiac resynchronization therapy (CRT).

Clinical Trial Description

Cardiac Resynchronization Therapy (CRT) has emerged as a promising therapeutic addition in patients with drug refractory heart failure (HF). Along with providing relief of symptoms of HF, cardiac resynchronization therapy defibrillators (CRT-D) are used for the prevention of sudden cardiac death (SCD). Although there are concerns that the defibrillation threshold (DFT) estimates are elevated in the heart failure (HF) patient population due to lower LV ejection fraction (EF) and left ventricular (LV) dysfunction, there is paucity of data available to evaluate this theory.

Recently, two different studies in a retrospective manner evaluated the energy requirements in patients receiving cardiac resynchronization therapy defibrillators (CRT-D). Burke et al analyzed DFTs in 50 patients each implanted with a cardiac resynchronization therapy defibrillators (CRT-D) device and an implantable cardioverter defibrillator (ICD). Although the ejection fraction (EF) in cardiac resynchronization therapy defibrillators (CRT- D) group was lower than the implantable cardioverter defibrillator (ICD) group, the mean defibrillation thresholds (DFTs) between the two groups were not significantly different (10.2 ± 6.1 J for the cardiac resynchronization therapy (CRT) group vs. 9.5 ± 5.0 J for the control group)14. In the ASSURE study, Doshi et al. showed that patients receiving cardiac resynchronization therapy defibrillators (CRT-D) devices do not have higher energy requirements when compared to patients receiving modern single or dual chamber implantable cardioverter defibrillators (ICDs). Although, there was a trend toward higher energy requirements found among patients with higher degrees of heart failure.

Major cardiac resynchronization therapy (CRT) trials have showed that cardiac resynchronization therapy (CRT) therapy has positive effects on ejection fraction (EF) and the heart failure (HF) condition of the patient over time. But, there is no study that has evaluated the defibrillation thresholds (DFTs) in the heart failure (HF) patients over time of receiving cardiac resynchronization therapy (CRT). This information will help the clinicians decide if they need to perform more invasive procedures during device implant to lower DFTs in patients who do not meet the defibrillation safety margin or they should just wait over time for the CRT to reduce the defibrillation threshold (DFT). Also, there is no published data about the stability of defibrillation thresholds (DFTs) in heart failure (HF) patients over time. The results from this study will also help to clarify whether it is safe to never test the defibrillation thresholds (DFTs) post-implant in this patient population. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00626093
Study type	Interventional
Source	Abbott Medical Devices
Contact
Status	Completed
Phase	Phase 4
Start date	January 2008
Completion date	April 2010

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02923726` - Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP	N/A
Recruiting	`NCT05175937` - REal World Assessment for Patients Implanted With Implantable CardioverTer DefibrIllatOr Using Bluetooth Technology
Completed	`NCT02026102` - A Pilot Trial of Patient Decision Aids for Implantable Cardioverter-Defibrillators (ICDs)	N/A
Completed	`NCT01262508` - Development of Algorithms to Predict Hemodynamic Instability	N/A
Completed	`NCT00998218` - Effect of Ranolazine on Arrhythmias and Microvolt T- Wave Alternans (MVTWA) Patients With LV Dysfunction	Phase 3
Completed	`NCT00845286` - Marathon, Genetics, Inflammation and the Cardiovascular System: MAGIC-Trial	N/A
Active, not recruiting	`NCT00562757` - Prospective Study to Identify Patients at Risk of Dangerous Ventricular Arrhythmias	N/A
Completed	`NCT00622453` - Arrhythmias in Myotonic Muscular Dystrophy	N/A
Completed	`NCT03833843` - Sudden Cardiac Death in Systemic Right Ventricle
Completed	`NCT04024865` - Domperidone and Risk of Serious Cardiac Events in Postpartum Women
Recruiting	`NCT05799833` - Low QRS Voltages in Young Healthy Individuals and Athletes
Recruiting	`NCT05694572` - Post-market Surveillance of Micorport CRM Cardiac Implantable Electronic Devices
Not yet recruiting	`NCT03622307` - Subcutaneous ICD Therapy Combined With VT Ablation for the Secondary Prevention of Sudden Cardiac Death	N/A
Recruiting	`NCT02058771` - Utilising Lifemap to Investigate Malignant Arrhythmia Therapy
Recruiting	`NCT02056509` - The Effect of Chest Compression and Ventilation Coordination During Cardiopulmonary Resuscitation.	N/A
Terminated	`NCT01948206` - Study of Paced QRS Duration as a Marker of Sudden Cardiac Death	N/A
Completed	`NCT01227785` - Next Generation INCEPTA Implantable Cardioverter Defibrillator (ICD) and Cardiac Resynchronization Therapy (CRT-D) Field Following Study	N/A
Completed	`NCT00534300` - Intravenous n-3 Fatty Acids and Ventricular Tachycardia in Patients With Implantable Cardioverter Defibrillator (ICD)-Pacemaker	Phase 1/Phase 2
Terminated	`NCT00524862` - Standard Drug Therapy vs. Implanted Defibrillator for Primary Prevention of Sudden Cardiac Death	N/A
Recruiting	`NCT00181233` - Imaging Techniques for Identifying Factors of Sudden Cardiac Death Risk